Evidence map›Paper›PMID 41960436›Full record

ArticleFrontiers in microbiology2026

Targeting the 5-HT7 receptor to block influenza virus entry: mechanistic insights and therapeutic potential of SB269970 HCl.

Yarou Gao, Xingjian Zhu, Jiaxin Ke, Yue Su, Xiaoqin Lian, Lefang Jiang, Mingxin Zhang, Yang Yu, Qun Peng, Xulin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yarou GaoInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Xingjian ZhuInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Jiaxin KeInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Yue SuInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Xiaoqin LianInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Lefang JiangInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Mingxin ZhangInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Yang YuInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Qun PengInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Xulin ChenInstitute of Medical Microbiology, Department of Immunology and Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza viruses persist as a significant global health challenge, with the emergence of drug-resistant strains limiting the effectiveness of current antiviral treatments. Inhibiting the early stages of viral replication is known to reduce virus-induced cytopathic effects; however, few therapeutics target these stages or the host factors supporting them, creating a critical gap in anti-influenza strategies development. This study aimed to address this gap by evaluating the antiviral potential of SB269970 HCl, a 5-HT7 receptor antagonist, against influenza viruses. We tested the efficacy of the compound using

Indexed as

5-HT7 receptorantiviral activityinfluenza virusin vitroin vivoSB269970 HClviral endocytosis

Identifiers

PMID41960436
PMCPMC13057298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.